TABLE 5.

Proportion of patients achieving PASI 75, PASI 90, and PASI 100 at week 4 and week 16 after secukinumab initiation categorized by adherence rate

PASI improvement (%)	Adherence rate				p‐value
	100%	75%–99%	50%–74%	<50%
	n (%) (95% CI)	n (%) (95% CI)	n (%) (95% CI)	n (%) (95% CI)
Week 4
N	13	30	30	21
PASI 75	10 (76.9%)	14 (46.7%)	7 (23.3%)	3 (14.3%)	0.001 † , *
	(54.0–99.8)	(28.8–64.5)	(8.2–38.5)	(0.0–29.3)
PASI 90	7 (53.9%)	8 (26.7%)	2 (6.7%)	3 (14.3%)	0.005 ‡ , *
	(26.8–81.0)	(10.8–42.5)	(0.0–15.6)	(0.0–29.3)
PASI 100	2 (15.4%)	3 (10.0%)	2 (6.7%)	1 (4.7%)	0.726 ‡
	(0.0–35.0)	(0.0–20.7)	(0.0–15.6)	(0.0–13.9)
Week 16
N	15	13	16	18
PASI 75	14 (93.3%)	12 (92.3%)	11 (68.8%)	9 (50.0%)	0.014 ‡ , *
	(80.7–100.0)	(77.8–100.0)	(46.1–91.5)	(26.9–73.1)
PASI 90	13 (86.7%)	11 (84.6%)	9 (56.3%)	9 (50.0%)	0.054 ‡
	(69.5–100.0)	(65.0–100.0)	(31.9–80.6)	(26.9–73.1)
PASI 100	11 (73.3%)	11 (84.7%)	7 (43.8%)	7 (38.9%)	0.026 † , *
	(51.0–95.7)	(65.0–100.0)	(19.4–68.1)	(16.4–61.4)

^* p‐value <0.05, indicating a statistically significant difference.

^† Overall p‐value (2‐sided) based on Chi‐square test.

^‡ Overall p‐value (2‐sided) based on Fisher's exact test.